Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica

Exclusion Criteria

• •Clinical evidence of giant cell arteritis.
• •Uncontrolled high blood pressure or cardiovascular disease.
• •High risk of VTE because of a history of VTE (DVT and/or PE) within 12 weeks prior to randomization or a history of recurrent (\>1) VTE (counting co-occurring DVT+PE as 1 single event).
• •Clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to PMR
• •Planned major surgical procedure during the study or medical history, blood abnormalities or any clinical condition that compromises inclusion.
• •Current smoker if age \>65 years.
• •Current active uncontrolled infection.
• •Treatment by probenecid.
• •Alkaline phosphatase (ALP) ≥2 x ULN.
• •Total bilirubin level (TBL) ≥1.5 x ULN.
• •Neutropenia (absolute neutrophil count \<1000 cells/uL) (\<1.00 x 103/uL or \<1.00 GI/L).
• •Lymphopenia (lymphocyte count \<500 cells/uL) (\<0.50 x 103/uL or \<0.50 GI/L).
• •Patient under court protection or protected adults